GlassScriptPhysician profile
April A Gordon
NPI 1558900902
$2,504.68
in general payments reported to CMS, 2019-2025
39 companies · $38.50 in 2025
The $38.50 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,251 · 2022: $1,100 · 2023: $71.54 · 2024: $43.13 · 2025: $38.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $153.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.32 | 2021-2024 | |
| Novo Nordisk INC | $196.97 | 2021-2022 | |
| Amgen INC. | $169.64 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $150.77 | 2022-2023 | Imbruvica |
| Incyte Corporation | $119.30 | 2022 | |
| Merck Sharp & Dohme LLC | $115.16 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $89.22 | 2021-2022 | |
| Eisai INC. | $86.05 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.94 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.39 | 2021-2022 | |
| Daiichi Sankyo INC. | $72.22 | 2022 | |
| Astellas Pharma US INC | $64.70 | 2021 | |
| Upsher-Smith Laboratories LLC | $57.33 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $52.39 | 2021 | |
| Dexcom, INC. | $50.39 | 2021-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $49.12 | 2021 | |
| Glaxosmithkline, LLC. | $46.06 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $44.17 | 2022 | |
| Clarus Therapeutics INC. | $39.98 | 2021 | |
| Boston Scientific Corporation | $38.50 | 2025 | General - Pain Management |
| Adc Therapeutics America, INC. | $37.66 | 2022 | |
| Janssen Biotech, INC. | $35.59 | 2022-2023 | Darzalex |
| Seagen INC. | $34.40 | 2022 | |
| Genentech USA, INC. | $34.36 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.03 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $26.15 | 2021 | |
| Lilly USA, LLC | $24.67 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $24.45 | 2022 | |
| Celgene Corporation | $21.75 | 2022 | |
| Bausch Health US, LLC | $21.44 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.39 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.50 | 2022 | |
| Blueprint Medicines Corporation | $18.88 | 2022 | |
| Puma Biotechnology, INC. | $17.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.01 | 2021 | |
| Abiomed | $16.56 | 2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $13.77 | 2022 | |
| Phadia US INC. | $13.16 | 2021 | |
| Medtronic, INC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.